Ushering in a New Era of Medical Education at NTHU
2.10.2021 08:00:00 EEST | Business Wire | Press release
National Tsing Hua University’s plan to establish a post-baccalaureate program in medicine has been approved at a recent cross-ministerial meeting held at the Ministry of Education. The school’s recruitment and admission application process will begin by the end of 2021, and the first class of government-sponsored students will be enrolled in September 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211001005043/en/
College of Life Science dean Kao Ruey-Ho (left) and Department of Medical Science chair Chen Linyi (right) prepare for the post-baccalaureate program in medicine. (Photo: National Tsing Hua University)
NTHU President Hocheng Hong said that NTHU already has a strong foundation in cross-disciplinary research in medical science, including big data analysis, application of artificial intelligence (AI), bioengineering, material science, and nuclear medicine, by which the school is well-positioned to train physicians specializing in more than one expertise. As such, this new program represents a quantum jump in medical education in Taiwan.
President Hocheng said that NTHU already has sufficient number of faculty members, funding, and infrastructure for the new program. In addition to the existing 180 faculty members teaching related courses, the program has recently recruited an additional 71 full-time faculty members, and 87 physician scientists from leading medical centers throughout Taiwan as adjunct faculty members. Moreover, the provisional office of this program has raised NT$2 billion for medical education. An ongoing plan for establishing a state-of-the-art teaching hospital and medical complex in the Taoyuan Aerotropolis next to the Taoyuan International Airport is currently being reviewed by the Ministry of Health and Welfare.
The post-baccalaureate program in medicine is a four-year program, open for graduates from all disciplines. The government-sponsored students will be required to serve in a public healthcare facility for six years. They will have an opportunity to undertake an additional two years of advanced training in a medical center.
NTHU will draw on its extensive experience in student recruitment to admit only those applicants who meet the stringent admission qualifications, the innovative student selection process could open a new path for medical education in Taiwan.
The post-baccalaureate program in medicine will be part of the future College of Life Sciences and Medicine (currently the College of Life Science). Dean of the College of Life Science, Kao Ruey-Ho, former Superintendent of Tzu Chi Medical Center, said that applicants who apply directly to NTHU will be evaluated based on test scores, transcripts, and interviews, to select students who have demonstrated academic excellence, as well as a passion for medicine and public welfare.
Government-sponsored students in the program will take several courses designed to prepare them for practicing in a rural area, such as Community Medicine Practicum, and make good use of AI diagnosis and telemedicine technology; they will also attend seminars on altruism and dedication to public health, which will be taught by laureates of the Medical Contribution Award.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211001005043/en/
Contact information
Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom